Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triamcinolone as Adjunctive to PRP for Proliferative Diabetic Retinopathy
NCT00443521Phase 3Completed
- Sponsor
- Universidade de São Paulo
- Start
- Mar 2005
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised trial of triamcinolone in proliferative diabetic retinopathy (PDR), sponsored by Universidade de São Paulo. Primary endpoints: Visual acuity (ETDRS) at 6 months and Optical coherence tomography at 6 months. Started Mar 2005; status: completed.
02
Drugs
triamcinolone
03
Conditions
proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on NCT00443521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00443521.